Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

See Remarks

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-01-24	Premium	back to issuer	Premium	Premium	Premium	Chief Executive Officer
2024-01-24	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-24	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-24	Premium	back to issuer	Premium	Premium	Premium	-
2024-01-24	Premium	back to issuer	Premium	Premium	Premium	See Remarks
2024-01-24	Premium	back to issuer	Premium	Premium	Premium	-
2023-03-10	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-02-09	Premium	acquired	Premium	Premium	Premium	See Remarks
2022-04-01	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-04-01	Premium	bought	Premium	Premium	Premium	See Remarks
2021-02-19	Premium	sold	Premium	Premium	Premium	-
2021-02-05	Premium	sold	Premium	Premium	Premium	-
2021-01-29	Premium	acquired	Premium	Premium	Premium	See Remarks
2021-01-11	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2021-01-11	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2021-01-08	Premium	acquired	Premium	Premium	Premium	See Remarks
2021-01-08	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2020-09-24	Premium	bought	Premium	Premium	Premium	-
2020-08-21	Premium	bought	Premium	Premium	Premium	-
2020-08-20	Premium	bought	Premium	Premium	Premium	-
2020-08-19	Premium	bought	Premium	Premium	Premium	-
2020-08-18	Premium	bought	Premium	Premium	Premium	-
2020-08-17	Premium	bought	Premium	Premium	Premium	-

ORTX - Orchard Therapeutics plc Stock Price, Fair Value and News

Latest Insider Trading transactions for ORTX